Background: Cognitive impairment in MS impacts negatively on many patients at all disease
stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert …

Patients with multiple sclerosis who develop progressive disability from onset without relapses
or remissions pose difficulties in diagnosis, monitoring of disease activity and treatment. …

… function of macrophages and the pharmacokinetic properties of USPIO in their role as
magnetic resonance imaging (MRI) contrast agents which are taken up by these cells; and (b) to …

Few studies have directly compared the clinical features of neuropathic and non-neuropathic
pains. For this purpose, the French Neuropathic Pain Group developed a clinician-…

Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

Background The course and prognosis of childhood-onset multiple sclerosis have not been
well described. Methods We used data from 13 adult neurology departments affiliated with …

The unique clinical characteristics of primary progressive multiple sclerosis (PPMS) pose
particular diagnostic difficulties, both in excluding other causes of progressive syndromes and …

Objective To describe clinical and radiologic features associated with myelin oligodendrocyte
glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess …

… 7With the possible exception of interferon-/,B "I these trials have only shown a modest,
ifany, beneficial effect on the … Suppression of B lymphocyte function. 7 Imniunol 1986;137:727-32. …